Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 28-02 / BIG 1-01 (HERA) 

HERA: A randomized, three-arm, multicenter comparison of 1 year and 2 years of herceptin vs. no herceptin in women with HER2 positive primary breast cancer who have completed adjuvant chemotherapy

DESIGN

Design Trial 28-02

Results & Publications


Presentations


Publications

Study Chairs
IBCSG: Dr. Olivia Pagani - Mendrisio, Switzerland
BIG: Dr. Martine J. Piccart - Brussels, Belgium

Trial Coordinator
Sabrina Ribeli-Hofmann
IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 389 93 91
Fax: +41 31 389 92 73
Email: ibcsg28-02_big0101@ibcsg.org

Date of Activation
June 1998

Date of Closure
June 1, 2002

Targeted Accrual
2730 patients

Final Accrual
2890 patients


Results Publications Results & Publications


News

11.12.2008:
BIG 1-98: Results from sequential treatment analysis and updated monotherapy analysis

11.12.2008:
Brinker Award for Richard Gelber and Aron Goldhirsch

11.12.2008:
All presentations from investigators' meetings at San Antonio Breast Cancer Symposium now

All News

 
  Print